zoledronic acid has been researched along with Cancer of Lung in 154 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 53 (34.42) | 29.6817 |
| 2010's | 82 (53.25) | 24.3611 |
| 2020's | 19 (12.34) | 2.80 |
| Authors | Studies |
|---|---|
| Artioli, F; Bongiovanni, A; Burgio, MA; Fantini, M; Fausti, V; Foca, F; Forcignanò, MR; Guadalupi, V; Ibrahim, T; Menis, J; Mercatali, L; Miserocchi, A; Recine, F; Spadazzi, C; Stucci, SL | 1 |
| Gong, H; Xu, H; Zhang, G | 1 |
| Cao, W; Dong, N; Hu, A; Qi, Y; Xiang, S; Xiao, J; Zhang, P; Zou, D | 1 |
| Chen, YY; Ding, ZY; Fu, Y; Wang, PP; Zheng, Y | 1 |
| Aerxiding, P; Aosiman, A; Liu, J; Nuermaimaiti, G; Yuan, M | 1 |
| Hata, A; Hatachi, Y; Hidaka, Y; Hirashima, T; Kaneda, T; Katakami, N; Mori, M; Morita, S; Nishimura, T; Nishino, K; Ohnishi, H; Takase, N | 1 |
| Jukkola, A; Määttä, J; Mattila, PK; Petruk, N; Sandholm, J; Selander, KS; Siddiqui, A; Tadayon, S | 1 |
| Diel, I; Holtmann, L; Kerkmann, M; Link, H; Ohlmann, CH | 1 |
| Ando, Y; Arai, E; Hase, T; Ikuta, K; Ishiguro, N; Kikumori, T; Maeda, O; Mitsuma, A; Nishida, Y; Shimokata, T; Sugishita, M; Urakawa, H | 1 |
| Beidas, RS; Bekelman, JE; Ladage, VP; Mace, DS; Shulman, LN; Takvorian, SU; Wileyto, EP | 1 |
| Cruz, C; Miyashita, H; Smith, C | 1 |
| Ebisudani, T; Hosoi, A; Ikemura, S; Kakimi, K; Karasaki, T; Kawada, I; Kitano, K; Kobayashi, Y; Manabe, T; Masuzawa, K; Matsushita, H; Nagaoka, K; Nagayama, K; Nakajima, J; Nakamura, Y; Sato, M; Soejima, K; Suzuki, R; Takehara, T; Yasuda, H | 1 |
| Nachar, VR; Qin, A; Schepers, AJ; Tam, AH | 1 |
| Chen, D; Chen, X; Han, Y; Zang, X; Zhang, X; Zhou, J | 1 |
| Ebata, T; Ishiwata, T; Iwasawa, S; Saito, G; Takiguchi, Y; Tatsumi, K; Yoshino, I | 1 |
| Bian, W; Du, Y; Gao, Y; Huang, C; Liu, H; Liu, Q; Wan, L; Yang, X | 1 |
| Abbas, U; Axelrod, D; Bhasin, R; Bozzo, A; Deng, J; Deodat, M; Ghert, M; Masrouha, K; Sanger, S; Turcotte, R; Wariach, S; Wilson, D | 1 |
| Wu, W; Yu, G; Zhang, C; Zhang, M | 1 |
| Mi, J; Xu, Q; Zhang, Y | 1 |
| Evdokiou, A; Gao, S; Ko, CH; Lau, CB; Lee, JK; Leung, PC; Li, G; Luo, KW; Shiu, HT; Shum, WT; Siu, WS; Yue, GG | 1 |
| Higashino, M; Hozumi, T; Kogo, M; Kokubu, F; Matsui, M; Nagatani, A; Nakamura, S; Sasaki, T; Shimamoto, K; Sunaga, T; Takahashi, N | 1 |
| Cao, H; Nguyen, AL; Thinn, MM | 1 |
| Imamura, Y; Matsuda, S; Sano, K; Umeda, Y; Yoshida, H; Yoshimura, H | 1 |
| Igishi, T; Izumi, H; Kodani, M; Makino, H; Nishii-Ito, S; Sakamoto, T; Shimizu, E; Takeda, K; Tanaka, N; Touge, H; Ueda, Y; Yamaguchi, K; Yamasaki, A; Yanai, M | 1 |
| Berk, LB; Clarkson, JE; Clausen, CL; Cleary, SF; Demas, W; Derdel, JD; Kachnic, LA; Langer, C; Peters, CA; Pugh, SL; Rabinovitch, RA; Ramalingam, A; Rashtian, A; Seider, MJ; Tomblyn, M; Wyatt, G | 1 |
| Chen, W; Cui, Y; Liu, H; Liu, Y; Ma, R; Yu, Z; Zhan, H | 1 |
| Bastit, L; Guérif, S; Khemaies, S; Kouri, CE; Ktiouet, M; Lebret, T; Lortholary, A; Mouysset, JL; Murraciole, X | 1 |
| Afonso, R; Bosch-Barrera, J; Isla, D; Martínez, N | 1 |
| Chai, ZT; Gao, DM; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xu, HX; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY | 1 |
| Bahleda, R; Escudier, B; Gueutin, V; Izzedine, H; Rouvier, P; Soria, JC; Varga, A | 1 |
| Hayata, A; Ikeda, T; Nakanishi, H | 1 |
| Aoyagi, T; Ichimura, S; Mochizuki, K; Morii, T; Ohnishi, H; Ohtsuka, K; Satomi, K; Tajima, T; Yoshiyama, A | 2 |
| Açıkgöz, Y; Aksoy, S; Ozdemir, NY; Sendur, MA; Uncu, D; Zengin, N | 1 |
| Balakumaran, A; Chung, K; Dodge, T; Edelsberg, J; Glass, AG; Lamerato, L; Lopez, A; Oster, G; Richert-Boe, KE; Richhariya, A; Wolff, GG | 1 |
| Guo, RT; Li, XL; Li, Y; Luan, JW; Nie, D; Wu, J; You, QS; Zhang, LP | 1 |
| Della Coletta, R; dos Santos-Silva, AR; Flores, IL; Lopes, MA; Vargas, PA | 1 |
| Song, Z; Zhang, Y | 1 |
| Amiaud, J; Battaglia, S; Charrier, C; Gouin, F; Heymann, D; Kim, PP; Lamoureux, F; Odri, G; Redini, F | 1 |
| Atagi, S; Fukuoka, M; Hirashima, T; Murakami, H; Nakagawa, K; Nakanishi, Y; Okamoto, I; Sawa, T; Seto, T; Sugio, K; Takeda, K; Yamamoto, N; Yamanaka, T | 1 |
| Lu, S; Song, Z; Yang, S; Yang, X; Yu, Y; Zhang, J | 1 |
| Abiko, M; Harada, M; Sato, T; Shiono, S; Takanashi, I | 1 |
| Evdokiou, A; Fung, KP; Gao, S; Ko, CH; Lau, CB; Lee, JK; Leung, PC; Li, G; Luo, KW; Yue, GG | 1 |
| Campia, I; Gazzano, E; Ghigo, D; Kopecka, J; Orecchia, S; Riganti, C; Salaroglio, IC | 1 |
| Gao, D; Gao, L; Jia, B; Liu, Z; Sun, X; Wang, F; Yu, X; Zhang, C | 1 |
| Dai, K; Dass, CR; Li, H; Ouyang, Z; Qin, A; Xu, J; Zhai, Z | 1 |
| Daga, H; Hirashima, T; Miyamoto, N; Morishita, N; Okada, H; Okamoto, N; Otsuka, T; Sasada, S; Shiroyama, T; Suzuki, H; Taira, K; Takeda, K; Tamiya, M; Tokunaga, S | 1 |
| Gehi, D; Rubin, CD; Tachibana, I | 1 |
| Caraglia, M; De Rosa, G; Desiderio, V; Gazzano, E; Ghigo, D; Giordano, A; Kopecka, J; Lusa, S; Porto, S; Riganti, C; Salzano, G | 1 |
| Arai, S; Fukuda, K; Hara, E; Kita, K; Nanjo, S; Nishihara, H; Takeuchi, S; Uehara, H; Yamada, T; Yano, S | 1 |
| Gros Herguido, N; Guerrero-Vázquez, R; Martínez Brocca, MA; Moreno Reina, E; Navarro González, E | 1 |
| Epperla, N; Pathak, R | 1 |
| Cohen, PR | 1 |
| Gong, J; Li, P; Ma, J; Xie, F; Zhang, J | 1 |
| Cai, XH; Feng, CJ; Huang, CY; Liu, XK; Lu, Y; Wang, L; Wang, Y; Wang, YS; Xu, Y; Yao, WX; Yu, P; Zhou, J; Zhu, WJ | 1 |
| Banks, RE; Brown, JE; Cairns, DA; Coleman, RE; Hanby, AM; Holen, I; Marshall, H; Ottewell, PD; Peng, J; Selby, PJ; Speirs, V; Westbrook, JA; Wood, SL | 1 |
| Feng, C; Guo, F; Huang, C; Li, X; Liu, X; Qin, Q; Wang, Y | 1 |
| Bonanini, M; Fornaini, C; Giovannacci, I; Manfredi, M; Meleti, M; Merigo, E; Vescovi, P | 1 |
| Cserepes, M; Dobos, J; Hegedűs, B; Horváth, O; Izsák, V; Kenessey, I; Kói, K; Molnár, D; Tímár, J; Tóvári, J | 1 |
| Atkins, G; DeNichilo, MO; Evdokiou, A; Findlay, D; Hay, S; Ingman, W; Liapis, V; Panagopoulos, V; Ponomarev, V; Zannettino, A; Zinonos, I; Zysk, A | 1 |
| Goto, K; Kirita, K; Matsumoto, S; Niho, S; Udagawa, H; Umemura, S; Yoh, K | 1 |
| Bertolini, F; Codeluppi, M; Conte, PF; De Matteis, E; Frassoldati, A; Malavasi, N; Rossi, G; Venturelli, C | 1 |
| King, MM; Nelson, DA | 1 |
| Namazi, H | 1 |
| Chen, HQ; He, WZ; Li, ZM; Liao, ML; Lu, S; Wang, JJ; Xiang, JQ; Zhang, J; Zhou, XY; Zhou, Z | 1 |
| Barghout, V; Hatoum, HT; Lin, SJ; Lipton, A; Smith, MR | 1 |
| Chen, Q; Dong, M; Feng, FY; Feng, JF; Jiao, SC; Li, J; Liu, JW; Ren, J; Song, ST; Wang, XW; Wang, YJ; Wang, ZH; Xie, GR; Xu, N; Zhang, Y; Zhou, QH | 1 |
| Adachi, S; Fushiki, S; Horie, N; Kimura, S; Koto, K; Kubo, T; Maekawa, T; Matsui, T; Murata, H; Sakabe, T; Watanabe, M | 1 |
| Ariyoshi, N; Hosoi, A; Kakimi, K; Kondo, M; Nakagawa, K; Nakajima, J; Noguchi, A; Sakuta, K; Sato, K; Sato, S; Shiraishi, K; Yoshida, Y | 1 |
| Cheng, J; Wu, G; Wu, HG; Xue, J | 1 |
| Hanibuchi, M; Ikuta, K; Kakiuchi, S; Muguruma, H; Nishioka, Y; Ogino, H; Sone, S; Uehara, H; Yamada, T; Yano, S | 1 |
| Chang, JW; Hsieh, JJ; Hsu, T; Li, YY; Shen, YC; Wang, CH; Yeh, KY | 1 |
| Harries, M; Hayday, A; Laggner, U; Lopez, JS; Nestle, FO; O'Doherty, MJ; Perera, G; Sita-Lumsden, A; Warbey, VS | 1 |
| Argonza-Aviles, E; Ericson, SG; Gajra, A; Pandya, KJ; Warsi, GM; Wozniak, AJ | 1 |
| Boutsikou, E; Eleftheriadou, E; Kanakis, I; Karamanos, NK; Kontakiotis, T; Lithoxopoulou, H; Tzanakakis, G; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Hirsh, V | 2 |
| Tamási, L | 1 |
| Goto, H; Hanibuchi, M; Ikuta, K; Kakiuchi, S; Nishioka, Y; Ogino, H; Otsuka, S; Sone, S; Takahashi, T; Yamada, T; Yano, S | 1 |
| Izumi, K; Konaka, H; Miwa, S; Mizokami, A; Namiki, M; Nohara, T | 1 |
| Crawford, BS; Kraut, EH; McNulty, RM; Turowski, RC | 1 |
| Evdokiou, A; Findlay, DM; Hay, S; Labrinidis, A; Liapis, V | 1 |
| Hirsh, V; Langer, C | 1 |
| Guo, J; Han, YP; Li, MJ; Wang, XH; Zhang, WD; Zong, ZH | 1 |
| de Marinis, F; Ricciardi, S | 1 |
| Kobayashi, H; Minato, N; Shimmura, H; Tanabe, K; Tanaka, Y | 1 |
| Kong, LQ; Sun, HC; Tang, ZY; Wang, L; Wu, WZ; Xiong, YQ; Xu, HX; Zhang, W; Zhu, XD; Zhuang, PY | 1 |
| Chen, WS; Hu, XY; Jin, C; Li, WD; Ma, L; Zou, QF | 1 |
| Chen, YM; Saad, F; Tchekmedyian, NS | 1 |
| Hirsh, V; Jahanzeb, M | 1 |
| Athanasou, N; Balke, M; Campanacci, L; Gebert, C; Gibbons, M; Hogendoorn, P; Kroep, J; Picci, P; Taylor, R; Wass, J | 1 |
| Chang, HJ; Chang, JW; Li, YY; Liu, YC; Su, SP; Tsai, MC; Wang, CH; Yeh, KY | 1 |
| Bargagli, G; Conca, R; Cozzolino, A; Fiaschi, AI; Francini, E; Francini, F; Gotti, G; Martellucci, I; Miano, ST; Migali, C; Pascucci, A; Petrioli, R | 1 |
| Jahanzeb, M; Khan, R; Mahtani, R | 1 |
| Hildreth, BE; Lanigan, LG; Martin, CK; Pillai, SP; Rosol, TJ; Werbeck, JL; Wolfe, TD | 1 |
| Daphnis, E; Georgoulias, V; Giannakakis, K; Kokologiannakis, G; Kroustalakis, N; Liotsi, C; Lioudaki, E; Papadimitraki, E; Stylianou, K | 1 |
| Astone, A; Bagalà, C; Barone, C; Cassano, A; Di Salvatore, M; Orlandi, A; Quirino, M | 1 |
| Kobayashi, H; Minato, N; Tanabe, K; Tanaka, Y; Yagi, J | 1 |
| Bargagli, G; Francini, E; Francini, F; Miano, ST; Pascucci, A; Petrioli, R; Ruggiero, G | 1 |
| Botteman, MF; Carter, JA; Joshi, AD; Kaura, S | 2 |
| Fujitaka, K; Haruta, Y; Hattori, N; Ishikawa, N; Iwamoto, H; Kanehara, M; Kohno, N; Murai, H; Nagao, S; Ohshimo, S | 1 |
| Calderone, R; Leary, A; Nimako, K; O'Brien, ME; Popat, S | 1 |
| Chang, YC; Chen, JH; Cheng, JC; Chou, CH; Teng, CM; Tzen, KY | 1 |
| Aktas, I; Atalay, B; Aybar, B; Cetin, O; Emes, Y; Issever, H; Mandel, NM; Oncu, B; Yalcin, S | 1 |
| Curi, MM; Lascala, CA; Marques, MM; Martins, MA; Martins, MD; Migliorati, CA; Tenis, CA | 1 |
| Henk, HJ; Kaura, S; Teitelbaum, A | 1 |
| Furukawa, K; Hosaka, M; Ishida, J; Matsushima, Y; Saito, M | 1 |
| Chen, YM; Costa, L; Hadji, P; Kosmidis, P; Lipton, A | 1 |
| Chang, JW; Chen, SM; Hsieh, LL; Li, YY; Yeh, KY | 1 |
| Albert, I; Barbera, S; de Marinis, F; Engel-Riedel, W; Kosmidis, P; Kuo, HP; Manegold, C; Perez, JR; Sallo, V; Scagliotti, GV; Schallier, D; Schreurs, AJM | 1 |
| Gődény, M; Láng, I; Nagy, T; Rubovszky, G; Szász, A | 1 |
| Kagamu, H; Miura, S; Saijyo, Y | 1 |
| Goto, K; Kubota, K; Niho, S; Ohe, Y; Ohmatsu, H; Yoh, K | 1 |
| Tao, H; Wang, M; Wang, Y; Wang, Z; Yu, X | 1 |
| Mukherjee, K; Saha, A; Sonthalia, N; Talukdar, A | 1 |
| Balakumaran, A; Ciuleanu, TE; García-Sáenz, JA; Henry, DH; Hirsh, V; Jacobs, I; Kanarev, V; Krzakowski, M; Lipton, L; Manegold, C; Mehta, ND; Pereira, JR; Prabhash, K; Rodriguez, G; Scagliotti, GV; Siena, S; Solal-Celigny, P; Wang, H; Woll, PJ | 1 |
| Hassali, MA; Hassan, BA; Othman, SB; Weiderpass, E; Yusoff, ZB | 1 |
| Body, JJ; Brown, J; Coleman, R; Cook, R; Lipton, A; Smith, M | 1 |
| Arai, E; Futamura, N; Ishiguro, N; Kozawa, E; Nishida, Y; Urakawa, H | 1 |
| Bastit, L; El Kouri, C; Guérif, S; Ktiouet, M; Lebret, T; Lortholary, A; Mouysset, JL; Murraciole, X; Slimane, K | 1 |
| Harland, SJ; Oosterlinck, W; Rosen, L | 1 |
| Rosen, LS | 1 |
| de Souza, P; Gordon, D; Hirsh, V; Krzakowski, M; Pawlicki, M; Reitsma, D; Rosen, LS; Seaman, JJ; Tchekmedyian, S; Urbanowitz, G; Yanagihara, R; Zheng, M | 1 |
| Hohneker, J; Lacerna, L | 1 |
| Price, N | 1 |
| De Souza, P; Gordon, D; Hirsh, V; Krzakowski, M; Pawlicki, M; Reitsma, D; Rosen, LS; Seaman, J; Tchekmedyian, NS; Urbanowitz, G; Yanagihara, R; Zheng, M | 1 |
| Hiraga, T; Tamura, D; Ueda, A; Williams, PJ; Yoneda, T | 1 |
| Hei, YJ; Hirsh, V; Rosen, LS; Tchekmedyian, NS; Zheng, M | 1 |
| Kimura, S; Kuroda, J; Maekawa, T; Matsumoto, S; Nogawa, M; Sato, K; Segawa, H; Tanaka, F; Wada, H; Yuasa, T | 1 |
| Brown, JE; Coleman, RE; Cook, RJ; Hei, YJ; Lee, KA; Lipton, A; Major, P; Saad, F; Smith, M; Zheng, M | 1 |
| Antoniou, N; Bamias, A; Bozas, G; Deliveliotis, C; Dimopoulos, MA; Efstathiou, E; Kastritis, E; Kostakopoulos, A; Papadimitriou, C; Skarlos, D | 1 |
| Inoue, K; Kawada, K; Minami, H; Okabe, K; Sasaki, T; Sawamura, M; Takashima, S; Watanabe, T; Yagi, Y | 1 |
| Hines, E; Tanvetyanon, T | 1 |
| Khuri, F; Saba, N | 2 |
| Langer, CJ | 1 |
| Altun, B; Altundag, K; Elkiran, T; Gullu, I; Kurt, M; Onal, IK | 1 |
| Avcu, F; Ural, AU | 1 |
| Barutca, S; Erdogan, S; Koseoglu, K; Meydan, N; Yurekli, Y | 1 |
| Conroy, M; Cree, IA; Fernando, A; Knight, LA; Kurbacher, CM; Polak, M | 1 |
| Gouin, F; Heymann, D; Heymann, MF; Kamijo, A; Ory, B; Redini, F | 1 |
| Budman, DR; Calabro, A | 1 |
| Iguchi, H; Levine, AL; Nadella, MV; Rosol, TJ; Tannehill-Gregg, SH | 1 |
| Kenna, T; Mattarollo, SR; Nicol, AJ; Nieda, M | 1 |
| Akca, S; Bozcuk, H; Burgucu, D; Ekinci, D; Ozdogan, M; Ozturk, OH; Yildiz, M | 1 |
| Aguilera Tubet, C; Ballestero Diego, R; Roca Edreira, A; Villanueva Peña, A; Zubillaga Guerrero, S | 1 |
| Chang, JW; Chou, WC; Huang, JS; Li, YY; Liaw, CC; Wang, CH; Wang, HM; Yeh, KY | 1 |
| Budillon, A; Caraglia, M; Facchini, G; Fiore, F; Iaffaioli, RV; Maiolino, P; Nasti, G; Ottaiano, A; Ruberto, M; Santini, D; Striano, S; Tonini, G; Zeppetella, GL | 1 |
| Camlica, H; Duranyildiz, D; Oguz, H; Tas, F; Topuz, E; Yasasever, V | 1 |
| McKeage, K; Plosker, GL | 1 |
| Brown, JE; Coleman, RE; Cook, RJ; Hirsh, V; Langer, CJ; Lipton, A; Major, PP; Smith, MR | 1 |
| Kalomenidis, I; Karabela, S; Kollintza, A; Loutrari, H; Magkouta, S; Moschos, C; Papiris, SA; Psallidas, I; Roussos, C; Stathopoulos, GT; Zhou, Z | 1 |
| Fujii, Y; Fukui, I; Kijima, T; Okubo, Y; Suyama, T; Yonese, J | 1 |
19 review(s) available for zoledronic acid and Cancer of Lung
| Article | Year |
|---|---|
Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Drug Therapy, Combination; Humans; Ibandronic Acid; Lung Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid | 2021 |
Zoledronic acid in lung cancer with bone metastases: a review.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Zoledronic Acid | 2013 |
Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Differentiation; Cell Proliferation; Cell Survival; Humans; In Vitro Techniques; Lung Neoplasms; Osteosarcoma; Zoledronic Acid | 2018 |
Zoledronic acid-associated symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): report of baboon syndrome in a woman with recurrent metastatic breast cancer after receiving zoledronic acid.
Topics: Arm; Axilla; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Buttocks; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Diphosphonates; Drug Eruptions; Erythema; Female; Humans; Imidazoles; Intertrigo; Lung Neoplasms; Middle Aged; Mixed Tumor, Malignant; Syndrome; Zoledronic Acid | 2015 |
Regression of melanoma metastases following treatment with the n-bisphosphonate zoledronate and localised radiotherapy.
Topics: Apoptosis; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Melanoma; Middle Aged; T-Lymphocytes; TNF-Related Apoptosis-Inducing Ligand; Zoledronic Acid | 2009 |
Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer.
Topics: Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Morbidity; Peptides; Quality of Life; Zoledronic Acid | 2009 |
[Antitumor activity of zoledronic acid].
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Diphosphonates; Evidence-Based Medicine; Humans; Imidazoles; Lung Neoplasms; Treatment Outcome; Zoledronic Acid | 2009 |
Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Humans; Imidazoles; Incidence; Lung Neoplasms; Neoplasm Metastasis; Zoledronic Acid | 2010 |
Treatment of bone metastases in lung cancer: the actual role of zoledronic acid.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Practice Guidelines as Topic; Survival Analysis; Zoledronic Acid | 2009 |
Bisphosphonates in lung cancer: more than a palliative therapy?
Topics: Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Palliative Care; Zoledronic Acid | 2010 |
The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Zoledronic Acid | 2011 |
Bisphosphonates in lung cancer: can they provide benefits beyond prevention of skeletal morbidity?
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Lung; Lung Neoplasms; Zoledronic Acid | 2012 |
Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Carcinoma, Renal Cell; Cost-Benefit Analysis; Diphosphonates; Drug Costs; Europe; Health Care Costs; Humans; Imidazoles; Kidney Neoplasms; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Zoledronic Acid | 2012 |
Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Prostatic Neoplasms; Zoledronic Acid | 2002 |
Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.
Topics: Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Palliative Care; Zoledronic Acid | 2002 |
Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors.
Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Multiple Myeloma; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid | 2003 |
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clodronic Acid; Diphosphonates; Etidronic Acid; False Negative Reactions; Fluorodeoxyglucose F18; Humans; Ibandronic Acid; Imidazoles; Lung Neoplasms; Pamidronate; Positron-Emission Tomography; Predictive Value of Tests; Therapeutic Equivalency; Zoledronic Acid | 2005 |
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cost-Benefit Analysis; Diphosphonates; Drug Costs; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Lung Neoplasms; Multicenter Studies as Topic; Nerve Compression Syndromes; Pain; Spinal Cord Compression; United States; Zoledronic Acid | 2005 |
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Quality-Adjusted Life Years; Zoledronic Acid | 2008 |
26 trial(s) available for zoledronic acid and Cancer of Lung
| Article | Year |
|---|---|
Analysis of the Mechanism and Safety of Bisphosphonates in Patients with Lung Cancer and Bone Metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Cisplatin; Computational Biology; Deoxycytidine; Diphosphonates; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Safety; Young Adult; Zoledronic Acid | 2021 |
Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312).
Topics: Bone Neoplasms; Humans; Lung Neoplasms; Zoledronic Acid | 2023 |
Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Receptors, Antigen, T-Cell, gamma-delta; Zoledronic Acid | 2020 |
Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Osteoblasts; Palliative Care; Prostatic Neoplasms; Quality of Life; Radiopharmaceuticals; Safety; Survival Analysis; Zoledronic Acid | 2018 |
Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Disease-Free Survival; Docetaxel; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids; Zoledronic Acid | 2014 |
[Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].
Topics: Adult; Aged; Analgesics; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Colorectal Neoplasms; Creatinine; Diphosphonates; Double-Blind Method; Female; Fever; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Pain, Intractable; Pamidronate; Peptides; Prospective Studies; Vomiting; Zoledronic Acid | 2008 |
[Clinical analysis of therapeutic effect of zoledronic acid combined with radiotherapy for metastatic bone cancer].
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Bone Regeneration; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Pain; Pain Management; Radiotherapy; Zoledronic Acid | 2008 |
Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Docetaxel; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Taxoids; United States; Zoledronic Acid | 2010 |
[Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Peptides; Zoledronic Acid | 2010 |
Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Peptides; Treatment Outcome; Zoledronic Acid | 2011 |
Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; CD3 Complex; Cytotoxicity, Immunologic; Diphosphonates; Female; Humans; Imidazoles; Immunotherapy, Adoptive; Interleukin-2; Kidney Neoplasms; Lung Neoplasms; Lymphocyte Activation; Male; Middle Aged; Neoplasm Staging; Organophosphorus Compounds; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Zoledronic Acid | 2011 |
Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom.
Topics: Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cost-Benefit Analysis; Diphosphonates; Europe; Fractures, Bone; Health Care Costs; Humans; Hypercalcemia; Imidazoles; Lung Neoplasms; Middle Aged; Quality-Adjusted Life Years; Spinal Cord Compression; Zoledronic Acid | 2011 |
Bisphosphonate-related osteonecrosis: laser-assisted surgical treatment or conventional surgery?
Topics: Adult; Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Lasers, Solid-State; Low-Level Light Therapy; Lung Neoplasms; Male; Middle Aged; Peptides; Prostatic Neoplasms; Retrospective Studies; Zoledronic Acid | 2011 |
Treatment of bone metastases before the onset of pain.
Topics: Aged; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pain; Randomized Controlled Trials as Topic; Zoledronic Acid | 2013 |
Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Calcium; Carcinoma, Non-Small-Cell Lung; Dietary Supplements; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Vitamin D; Young Adult; Zoledronic Acid | 2012 |
Feasibility study of zoledronic acid plus cisplatin-docetaxel as first-line treatment for advanced non-small cell lung cancer with bone metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diphosphonates; Docetaxel; Female; Humans; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Taxoids; Zoledronic Acid | 2012 |
Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Hypercalcemia; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Syndromes; Spinal Cord Compression; Strontium; Zoledronic Acid | 2013 |
Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Denosumab; Diphosphonates; Double-Blind Method; Female; Follow-Up Studies; Humans; Imidazoles; International Agencies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; RANK Ligand; Small Cell Lung Carcinoma; Survival Rate; Young Adult; Zoledronic Acid | 2012 |
Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.
Topics: Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Palliative Care; Zoledronic Acid | 2002 |
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.
Topics: Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasms; Placebos; Zoledronic Acid | 2003 |
Bisphosphonates to prevent skeletal morbidity in patients with lung cancer with bone metastases.
Topics: Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Morbidity; Prognosis; Zoledronic Acid | 2004 |
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Double-Blind Method; Humans; Imidazoles; Lung Neoplasms; Placebos; Zoledronic Acid | 2004 |
Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidazoles; Lung Neoplasms; Middle Aged; Retrospective Studies; Zoledronic Acid | 2004 |
A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
Topics: Adult; Aged; Breast Neoplasms; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Hypercalcemia; Imidazoles; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Treatment Outcome; Zoledronic Acid | 2005 |
The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Musculoskeletal System; Quality of Life; Zoledronic Acid | 2007 |
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Canada; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Osteoclasts; Peptides; Retrospective Studies; Time Factors; Treatment Outcome; United States; Zoledronic Acid | 2008 |
110 other study(ies) available for zoledronic acid and Cancer of Lung
| Article | Year |
|---|---|
Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Denosumab; Drug Synergism; Female; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Prognosis; Retrospective Studies; Survival Analysis; Zoledronic Acid | 2021 |
Efficacy Evaluation of Zoledronic Acid Combined with Chemotherapy in the Treatment of Lung Cancer Spinal Metastases on Computed Tomography Images on Intelligent Algorithms.
Topics: Algorithms; Alopecia; Bayes Theorem; Bone Neoplasms; Cisplatin; Disease Progression; Humans; Lung Neoplasms; Pain; Spinal Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2022 |
Zoledronic acid enhances the efficacy of immunotherapy in non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cytokines; Immunologic Factors; Immunotherapy; Lung Neoplasms; Mice; Tumor Microenvironment; Zoledronic Acid | 2022 |
Zoledronic acid-associated osteonecro sis of the jaw in patients with EGFR-sensitive mutant lung cancer: two case reports.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; ErbB Receptors; Humans; Lung Neoplasms; Quality of Life; Zoledronic Acid | 2023 |
CD73 regulates zoledronate-induced lymphocyte infiltration in triple-negative breast cancer tumors and lung metastases.
Topics: Animals; Humans; Imidazoles; Lung Neoplasms; Mice; Neoplasm Recurrence, Local; T-Lymphocytes; Triple Negative Breast Neoplasms; Zoledronic Acid | 2023 |
Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Calcium, Dietary; Denosumab; Dietary Supplements; Female; Germany; Guideline Adherence; Humans; Lung Neoplasms; Male; Oncologists; Practice Patterns, Physicians'; Prostatic Neoplasms; Retrospective Studies; Surveys and Questionnaires; Vitamin D; Vitamins; Zoledronic Acid | 2020 |
Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Collagen Type I; Denosumab; Disease Progression; Female; Follow-Up Studies; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Peptides; Prognosis; Prospective Studies; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2020 |
Association of Behavioral Nudges With High-Value Evidence-Based Prescribing in Oncology.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Choice Behavior; Denosumab; Female; Humans; Lung Neoplasms; Male; Medical Oncology; Middle Aged; Oncologists; Practice Patterns, Physicians'; Prostatic Neoplasms; Zoledronic Acid | 2020 |
Risk factors of skeletal-related events in patients with bone metastasis from non-small cell lung cancer undergoing treatment with zoledronate-a post hoc analysis of a randomized clinical trial.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lung Neoplasms; Male; Middle Aged; Musculoskeletal Abnormalities; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; Zoledronic Acid | 2021 |
Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non-Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Retrospective Studies; Zoledronic Acid | 2021 |
Dual-targeting tumor cells and tumor associated macrophages with lipid coated calcium zoledronate for enhanced lung cancer chemoimmunotherapy.
Topics: Calcium; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lipids; Lung Neoplasms; Macrophages; Male; Tumor Microenvironment; Tumor-Associated Macrophages; Zoledronic Acid | 2021 |
Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents.
Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Denosumab; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Risk Factors; Spinal Cord Compression; Zoledronic Acid | 2021 |
Zoledronic acid re‑sensitises gefitinib‑resistant lung cancer cells by inhibiting the JAK/STAT3 signalling pathway and reversing epithelial‑mesenchymal transition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Gefitinib; Humans; Janus Kinases; Lung Neoplasms; Mice; Phosphorylation; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays; Zoledronic Acid | 2021 |
Camrelizumab plus Zoledronic Acid Showed Sustained Efficacy in a Patient with Cranial and Spinal Metastases from Lung Adenocarcinoma.
Topics: Adenocarcinoma of Lung; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Spinal Neoplasms; Zoledronic Acid | 2021 |
Lung adenocarcinoma presents with diffuse bone metastasis.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Zoledronic Acid | 2021 |
Evaluation of the combined use of metronomic zoledronic acid and Coriolus versicolor in intratibial breast cancer mouse model.
Topics: Administration, Metronomic; Agaricales; Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Female; Humans; Imidazoles; Liver Neoplasms; Lung Neoplasms; Mammary Neoplasms, Animal; Mice, Inbred BALB C; Mice, Nude; Osteoclasts; Tibia; Zoledronic Acid | 2017 |
The Association between Fever and Prognosis in Lung Cancer Patients with Bone Metastases Receiving Zoledronic Acid.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Fever; Humans; Imidazoles; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Leukocytes; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prognosis; Proportional Hazards Models; Retrospective Studies; Zoledronic Acid | 2017 |
Metastatic Hepatocellular Carcinoma Treated With Zoledronic Acid.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Lung Neoplasms; Male; Zoledronic Acid | 2018 |
Mandibular metastasis as the first clinical indication of occult lung adenocarcinoma with multiple metastases: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Biopsy; Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Female; Gefitinib; Humans; Imidazoles; Immunohistochemistry; Lung; Lung Neoplasms; Mandible; Mandibular Neoplasms; Neoplasm Grading; Neoplasm Staging; Quinazolines; Thyroid Neoplasms; Treatment Outcome; Zoledronic Acid | 2018 |
Acute-phase reaction induced by zoledronate and its effect on prognosis of patients with advanced non-small cell lung cancer.
Topics: Acute-Phase Reaction; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Count; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphocyte Activation; Male; Middle Aged; Prognosis; Receptors, Antigen, T-Cell, gamma-delta; Retrospective Studies; Survival Analysis; T-Lymphocytes; Zoledronic Acid | 2018 |
Cost-effectiveness of standard utilization of zoledronic acid for bone metastases from advanced lung cancer in China.
Topics: Bone Density Conservation Agents; Bone Neoplasms; China; Cost-Benefit Analysis; Humans; Lung Neoplasms; Models, Economic; Quality-Adjusted Life Years; Zoledronic Acid | 2019 |
[Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient-nurse satisfaction].
Topics: Adult; Aged; Aged, 80 and over; Benchmarking; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Feasibility Studies; Female; Home Infusion Therapy; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Nurse-Patient Relations; Nursing Staff; Patient Compliance; Patient Satisfaction; Personal Satisfaction; Prospective Studies; Prostatic Neoplasms; Surveys and Questionnaires; Zoledronic Acid | 2013 |
Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dendritic Cells; Diphosphonates; Heterografts; Humans; Imidazoles; Immunosuppression Therapy; Indoles; Interleukin-12 Subunit p40; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasm Transplantation; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Zoledronic Acid | 2013 |
Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven.
Topics: Acute Kidney Injury; Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Carcinoma, Renal Cell; Cisplatin; Cyclophosphamide; Diphosphonates; Doxorubicin; Female; Glutamates; Guanine; Humans; Imidazoles; Indoles; Interferons; Kidney Tubules; Lung Neoplasms; Lymphoma, B-Cell; Male; Mediastinal Neoplasms; Middle Aged; Necrosis; Nephrectomy; Pemetrexed; Prednisone; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases; Vincristine; Zoledronic Acid | 2013 |
[Use of zoledronic acid for lung cancer with bone metastases - a study on reossification of osteolytic bone metastases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Osteoporosis; Quality of Life; Young Adult; Zoledronic Acid | 2013 |
Lung cancer cell line sensitivity to Zoledronic acid is BAX-dependent.
Topics: Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Imidazoles; Lung Neoplasms; RNA Interference; Zoledronic Acid | 2013 |
Longest survival of lung metastatic ameloblastoma with a rare cause of malignant hypercalcemia.
Topics: Ameloblastoma; Bone Density Conservation Agents; Diphosphonates; Follow-Up Studies; Humans; Hypercalcemia; Imidazoles; Lung Neoplasms; Male; Mandibular Neoplasms; Middle Aged; Polydipsia; Polyuria; Treatment Refusal; Zoledronic Acid | 2014 |
Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Pamidronate; Prostatic Neoplasms; Zoledronic Acid | 2014 |
[Long-term results of personalized treatment in 72 breast cancer patients who failed chemotherapy].
Topics: Adult; Aged; Aromatase Inhibitors; Bone Density Conservation Agents; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Diphosphonates; Drugs, Chinese Herbal; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Lung Neoplasms; Medicine, Chinese Traditional; Middle Aged; Neoplasm Staging; Nitriles; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Remission Induction; Retrospective Studies; Survival Rate; Treatment Failure; Triazoles; Zoledronic Acid | 2013 |
Synchronous antiresorptive osteonecrosis of the jaws and breast cancer metastasis.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diagnostic Imaging; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Maxillary Neoplasms; Middle Aged; Zoledronic Acid | 2014 |
Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases.
Topics: Aged; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pleural Effusion, Malignant; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2014 |
Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Diphosphonates; Disease Models, Animal; Disease Progression; Drug Evaluation, Preclinical; Female; Humans; Imidazoles; Lung Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Sarcoma, Ewing; Tumor Burden; Tumor Cells, Cultured; Zoledronic Acid | 2014 |
Everolimus and zoledronic acid--a potential synergistic treatment for lung adenocarcinoma bone metastasis.
Topics: Animals; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Drug Synergism; Drug Therapy, Combination; Everolimus; Humans; Imidazoles; Lung Neoplasms; Mice; Neoplasm Invasiveness; Phosphorylation; Ribosomal Protein S6 Kinases, 70-kDa; Sirolimus; Zoledronic Acid | 2014 |
[A case of recurrent lung cancer with bone metastases treated with tegafur-uracil and zoledronic acid for long-term survival].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Male; Recurrence; Tegafur; Time Factors; Treatment Outcome; Uracil; Zoledronic Acid | 2014 |
The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
Topics: Administration, Metronomic; Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Camellia sinensis; Cell Line, Tumor; Diphosphonates; Drug Therapy, Combination; Female; Imidazoles; Liver Neoplasms; Luminescent Measurements; Lung Neoplasms; Mammary Neoplasms, Experimental; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; Osteolysis; Plant Extracts; Zoledronic Acid | 2015 |
Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma.
Topics: Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Cell Proliferation; Cells, Cultured; Cholesterol; Diphosphonates; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; ras Proteins; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; STAT3 Transcription Factor; T-Lymphocytes; Terpenes; Tumor Cells, Cultured; Zoledronic Acid | 2015 |
Molecular imaging of tumor-infiltrating macrophages in a preclinical mouse model of breast cancer.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Diphosphonates; Docetaxel; Female; Imidazoles; Lectins, C-Type; Lung Neoplasms; Macrophages; Mammary Neoplasms, Experimental; Mannose Receptor; Mannose-Binding Lectins; Mice; Mice, Inbred BALB C; Receptors, Cell Surface; Sensitivity and Specificity; Spectroscopy, Near-Infrared; Taxoids; Zoledronic Acid | 2015 |
Evaluation of Bone Metastasis Using Serial Measurements of Serum N-Telopeptides of Type I Collagen in Patients with Lung Cancer: A Prospective Study.
Topics: Adult; Aged; Bone Neoplasms; Collagen Type I; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Peptides; Prospective Studies; Zoledronic Acid | 2015 |
Treatment of Hypertrophic Osteoarthropathy With Underlying Pulmonary Adenocarcinoma Using Zoledronic Acid.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Analgesics, Opioid; Bone Density Conservation Agents; Diphosphonates; Glucocorticoids; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Osteoarthropathy, Secondary Hypertrophic; Pain Management; Pain Measurement; Pneumonectomy; Treatment Outcome; Zoledronic Acid | 2015 |
Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells.
Topics: Animals; Apoptosis; ATP-Binding Cassette Transporters; Blotting, Western; Bone Density Conservation Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Diphosphonates; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Oxidative Stress; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
Organ-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancer.
Topics: Animals; Benzoquinones; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Diphosphonates; HSP90 Heat-Shock Proteins; Humans; Imidazoles; Lactams, Macrocyclic; Liver Neoplasms; Lung Neoplasms; Male; Mice; Organ Specificity; Proto-Oncogene Mas; Proto-Oncogene Proteins c-raf; Small Cell Lung Carcinoma; Zoledronic Acid | 2016 |
Advanced thyroid carcinoma in pregnancy: case report of two pregnancies.
Topics: Adenocarcinoma, Follicular; Adult; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Iodine Radioisotopes; Lung Neoplasms; Lymph Node Excision; Metastasectomy; Pregnancy; Pregnancy Complications, Neoplastic; Radiotherapy; Spinal Neoplasms; Thyroid Neoplasms; Thyroidectomy; Zoledronic Acid | 2015 |
Hypocalcemia Secondary to Zoledronate Therapy in a Patient With Low Vitamin D Level.
Topics: Bone Density Conservation Agents; Calcium; Diphosphonates; Humans; Hypocalcemia; Hypoparathyroidism; Imidazoles; Lung Neoplasms; Male; Middle Aged; Risk Factors; Small Cell Lung Carcinoma; Vitamin D Deficiency; Zoledronic Acid | 2015 |
The bisphosphonate zoledronic acid effectively targets lung cancer cells by inhibition of protein prenylation.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Diphosphonates; Drug Synergism; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, SCID; Protein Prenylation; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diphosphonates; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pamidronate; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2016 |
CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment.
Topics: Adaptor Proteins, Signal Transducing; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Microfilament Proteins; Molecular Targeted Therapy; Nuclear Proteins; Odds Ratio; Predictive Value of Tests; Proportional Hazards Models; Randomized Controlled Trials as Topic; Reproducibility of Results; Zoledronic Acid | 2016 |
Development of Stemness in Cancer Cell Lines Resistant to the Anticancer Effects of Zoledronic Acid.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Blotting, Western; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Diphosphonates; Drug Resistance, Neoplasm; Humans; Imidazoles; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Osteosarcoma; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2016 |
Zoledronic acid increases the antitumor effect of gefitinib treatment for non-small cell lung cancer with EGFR mutations.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mutation; Quinazolines; STAT3 Transcription Factor; Zoledronic Acid | 2016 |
Autofluorescence as indicator for detecting the surgical margins of medication-related osteonecrosis of the jaws.
Topics: Aged; Aged, 80 and over; Bicuspid; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Neoplasms; Breast Neoplasms; Cementoplasty; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Laser Therapy; Lasers, Solid-State; Lung Neoplasms; Male; Margins of Excision; Middle Aged; Multiple Myeloma; Optical Imaging; Postoperative Complications; Tooth Extraction; Zoledronic Acid | 2016 |
KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Movement; Cell Proliferation; Cisplatin; Diphosphonates; Dose-Response Relationship, Drug; Genetic Predisposition to Disease; Humans; Imidazoles; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, SCID; Mutation; Neoplasm Invasiveness; Neovascularization, Pathologic; Phenotype; Proto-Oncogene Proteins p21(ras); Signal Transduction; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays; Zoledronic Acid | 2016 |
Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytotoxicity, Immunologic; Diphosphonates; Female; Humans; Imidazoles; Immunotherapy, Adoptive; Lung Neoplasms; Lymphocyte Activation; Mice, Inbred NOD; Mice, SCID; Osteolysis; Phenotype; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes, Cytotoxic; Time Factors; Xenograft Model Antitumor Assays; Zoledronic Acid | 2017 |
Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Survival Analysis; Zoledronic Acid | 2017 |
Pulmonary strongyloidiasis mimicking cancer symptoms: a case of hyperinfection in a patient with metastatic lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchoalveolar Lavage Fluid; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Dexamethasone; Diagnosis, Differential; Diphosphonates; Gemcitabine; Humans; Imidazoles; Immunocompromised Host; Lung Diseases, Parasitic; Lung Neoplasms; Male; Strongyloidiasis; Superinfection; Zoledronic Acid | 2008 |
Hypertrophic osteoarthropathy effectively treated with zoledronic acid.
Topics: Bone Density Conservation Agents; Carcinoma, Bronchogenic; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Middle Aged; Osteoarthropathy, Secondary Hypertrophic; Zoledronic Acid | 2008 |
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity: a novel molecular mechanism.
Topics: Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Osteoclasts; Survival Rate; Zoledronic Acid | 2008 |
Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; bcl-2-Associated X Protein; bcl-X Protein; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Diphosphonates; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Humans; Imidazoles; Immunoenzyme Techniques; Incidence; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Peptides; Proto-Oncogene Proteins c-bcl-2; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2008 |
Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Databases, Factual; Diphosphonates; Female; Humans; Imidazoles; Insurance Claim Reporting; Lung Neoplasms; Male; Medical Records; Middle Aged; Prostatic Neoplasms; Retrospective Studies; United States; Zoledronic Acid | 2008 |
Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model.
Topics: Animals; Cell Proliferation; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Imidazoles; Lung Neoplasms; Mice; Osteosarcoma; Protein Prenylation; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2009 |
Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cells, Cultured; Colorectal Neoplasms; Cytokines; Cytotoxicity, Immunologic; Diphosphonates; Female; Humans; Imidazoles; Immunophenotyping; Immunotherapy, Adoptive; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; RNA; T-Lymphocytes; Zoledronic Acid | 2008 |
Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Humans; Imidazoles; Immunohistochemistry; Immunotherapy; Lung Neoplasms; Male; Mice; Mice, SCID; Parathyroid Hormone-Related Protein; Radiography; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays; Zoledronic Acid | 2009 |
Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells.
Topics: Animals; Apoptosis; Blotting, Western; Bone Density Conservation Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Survival; Diphosphonates; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Organophosphonates; Quinazolines; Transplantation, Heterologous; Zoledronic Acid | 2009 |
The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Disease Progression; Drug Administration Schedule; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pain; Proportional Hazards Models; Treatment Outcome; Zoledronic Acid | 2009 |
A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Endothelin-1; Humans; Imidazoles; Killer Cells, Natural; Lung Neoplasms; Male; Mice; Mice, Inbred ICR; Mice, SCID; Osteoblasts; Osteolysis; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2009 |
A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy.
Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Pleural Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2009 |
Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Jaw Diseases; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Retrospective Studies; Spinal Cord Compression; Time Factors; Treatment Outcome; Zoledronic Acid | 2009 |
Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model.
Topics: Animals; Apoptosis; Blotting, Western; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Caspases; Cell Proliferation; Diphosphonates; Imidazoles; Lung Neoplasms; Male; Osteosarcoma; Rats; Rats, Inbred F344; Zoledronic Acid | 2010 |
[Zoledronic acid blocks cell cycle and induces apoptosis in lung cancer cell line 95D cells and their mechanisms of action].
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Cycle; Cell Line, Tumor; Diphosphonates; Dose-Response Relationship, Drug; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Survivin; Zoledronic Acid | 2009 |
Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Carcinoma, Renal Cell; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Immunotherapy, Adoptive; Interferon-gamma; Interleukin-2; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; T-Lymphocytes; Transplantation, Autologous; Treatment Outcome; Zoledronic Acid | 2010 |
Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Clodronic Acid; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Liposomes; Liver Neoplasms, Experimental; Lung Neoplasms; Macrophages; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Xenograft Model Antitumor Assays; Zoledronic Acid | 2010 |
Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Lung Neoplasms; Male; Neoplasms; Orchiectomy; Placebos; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2010 |
Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Giant Cell Tumor of Bone; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Osteoclasts; Treatment Outcome; Tumor Cells, Cultured; Young Adult; Zoledronic Acid | 2010 |
Zoledronic acid induces cell-cycle prolongation in murine lung cancer cells by perturbing cyclin and Ras expression.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Diphosphonates; Diterpenes; Down-Regulation; E2F Transcription Factors; Imidazoles; Lung Neoplasms; Mevalonic Acid; Mice; Mice, Inbred BALB C; Phosphorylation; Protein Transport; ras Proteins; Retinoblastoma Protein; Zoledronic Acid | 2011 |
Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice.
Topics: Amputation, Surgical; Animals; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Dog Diseases; Dogs; Female; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Invasiveness; Osteosarcoma; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2011 |
Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Glomerulonephritis; Humans; Imidazoles; Lung Neoplasms; Male; Renal Dialysis; Small Cell Lung Carcinoma; Treatment Outcome; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2011 |
Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line.
Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclins; Diphosphonates; G1 Phase; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Survivin; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2011 |
Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Dental Care; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Jaw Diseases; Lung Neoplasms; Male; Middle Aged; Osteonecrosis; Peptides; Periodontal Diseases; Radiography, Panoramic; Risk Factors; Tooth Extraction; Zoledronic Acid | 2011 |
Regression of a primary pulmonary adenocarcinoma after zoledronic acid monotherapy.
Topics: Adenocarcinoma; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Middle Aged; Neoplasm Regression, Spontaneous; Zoledronic Acid | 2011 |
Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease--a short communication.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2011 |
MMP-9 from sublethally irradiated tumor promotes Lewis lung carcinoma cell invasiveness and pulmonary metastasis.
Topics: Animals; Carcinoma, Lewis Lung; Chick Embryo; Diphosphonates; Imidazoles; Lung Neoplasms; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred C57BL; Neoplasm Invasiveness; Zoledronic Acid | 2012 |
Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lasers, Semiconductor; Low-Level Light Therapy; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Platelet-Rich Plasma; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Treatment Outcome; Zoledronic Acid | 2012 |
Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Lung Neoplasms; Male; Medicare Part C; Middle Aged; Outcome Assessment, Health Care; Retrospective Studies; United States; Zoledronic Acid | 2012 |
Efficacy of vinorelbine and zoledronate combination therapy against postoperative recurrence of lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Male; Neoplasm Staging; Recurrence; Vinblastine; Vinorelbine; Zoledronic Acid | 2012 |
Low-dose zoledronic acid reduces spinal cord metastasis in pulmonary adenocarcinoma with neuroendocrine differentiation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Cell Differentiation; Cell Line, Tumor; Cloning, Molecular; Diphosphonates; Dose-Response Relationship, Drug; Flow Cytometry; Gene Knockdown Techniques; Green Fluorescent Proteins; Imidazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Neoplasm Transplantation; Neural Cell Adhesion Molecules; RNA, Small Interfering; Spinal Cord Neoplasms; Transfection; Zoledronic Acid | 2012 |
Successful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Diphosphonates; Humans; Hyperthermia, Induced; Imidazoles; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Zoledronic Acid | 2013 |
[Management of bone metastasis originating from lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Quality of Life; Zoledronic Acid | 2012 |
Treatment of hypertrophic osteoarthropathy in the case of pulmonary metastasis secondary-to-nasopharyngeal carcinoma with zoledronic acid: an enlightening experience.
Topics: Adult; Bone Density Conservation Agents; Carcinoma; Diagnosis, Differential; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Lymphatic Metastasis; Male; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Osteoarthropathy, Secondary Hypertrophic; Palliative Care; Tomography, X-Ray Computed; Zoledronic Acid | 2012 |
Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Chi-Square Distribution; Cisplatin; Cyclophosphamide; Deoxycytidine; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Hypercalcemia; Imidazoles; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Pamidronate; Parathyroid Hormone-Related Protein; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Taxoids; Young Adult; Zoledronic Acid | 2012 |
Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.
Topics: Aged; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Osteolysis; Peptides; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2013 |
Hyaluronan synthesis inhibitor supplements the inhibitory effects of zoledronic acid on bone metastasis of lung cancer.
Topics: Animals; Base Sequence; Blotting, Western; Bone Neoplasms; Diphosphonates; DNA Primers; Female; Humans; Hyaluronic Acid; Imidazoles; In Situ Nick-End Labeling; Lung Neoplasms; Mice; Mice, Inbred C57BL; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Zoledronic Acid | 2013 |
Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient-nurse satisfaction.
Topics: Adult; Aged; Aged, 80 and over; Attitude of Health Personnel; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Feasibility Studies; Female; Fractures, Bone; Home Infusion Therapy; Humans; Imidazoles; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Nurses, Community Health; Osteonecrosis; Patient Compliance; Patient Satisfaction; Physicians; Prospective Studies; Prostatic Neoplasms; Zoledronic Acid | 2013 |
Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
Topics: Animals; Apoptosis; Blotting, Western; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Separation; Cell Survival; Diphosphonates; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Female; Flow Cytometry; Humans; Imidazoles; Luciferases; Lung Neoplasms; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Neoplasm Invasiveness; Neoplasm Metastasis; Osteoclasts; Time Factors; Zoledronic Acid | 2004 |
Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Small Cell; Cell Proliferation; Diphosphonates; Drug Interactions; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Transplantation, Heterologous; Tumor Cells, Cultured; Zoledronic Acid | 2005 |
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Bone Regeneration; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cohort Studies; Collagen; Collagen Type I; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasms; Peptides; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Risk Assessment; Risk Factors; Time Factors; Zoledronic Acid | 2005 |
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alopecia; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Imidazoles; Life Tables; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Orchiectomy; Pain; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, High-Energy; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Zoledronic Acid | 2005 |
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Time Factors; Zoledronic Acid | 2005 |
Role of zoledronic acid in the setting of bone metastases from non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Squamous Cell; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Lung Neoplasms; Middle Aged; Osteoarthropathy, Secondary Hypertrophic; Zoledronic Acid | 2005 |
Acute tumor lysis syndrome triggered by zoledronic Acid in a patient with metastatic lung adenocarcinoma.
Topics: Acute Disease; Adenocarcinoma; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Treatment Outcome; Tumor Lysis Syndrome; Zoledronic Acid | 2005 |
Radiosensitizing effect of zoledronic acid in small cell lung cancer.
Topics: Bone Density Conservation Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Diphosphonates; Genes, ras; Humans; Imidazoles; Lung Neoplasms; Radiation-Sensitizing Agents; Signal Transduction; Zoledronic Acid | 2005 |
Reversible metastatic visceral calcification detected by 99mTc-methylene diphosphonate bone scanning in breast cancer.
Topics: Antineoplastic Agents; Bone and Bones; Breast Neoplasms; Calcification, Physiologic; Calcium; Diphosphonates; Female; Heart Neoplasms; Humans; Imidazoles; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Technetium Tc 99m Medronate; Thyroid Neoplasms; Time Factors; Zoledronic Acid | 2005 |
Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Alendronate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caspase 3; Caspase 7; Caspases; Cell Line, Tumor; Cell Survival; Cisplatin; Clodronic Acid; Diphosphonates; Energy Metabolism; Female; Humans; Imidazoles; Inhibitory Concentration 50; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured; Zoledronic Acid | 2005 |
Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Models, Animal; Imidazoles; Lung Neoplasms; Male; Mice; Mice, Inbred C3H; Osteosarcoma; Survival Analysis; Zoledronic Acid | 2005 |
Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cytoplasm; Deoxycytidine; Diphosphonates; DNA Fragmentation; Drug Antagonism; Drug Synergism; Epirubicin; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemcitabine; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Prostatic Neoplasms; Zoledronic Acid | 2006 |
The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Division; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Osteoprotegerin; Tibia; Transplantation, Heterologous; Zoledronic Acid | 2006 |
Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Concanavalin A; Cytotoxicity, Immunologic; Diphosphonates; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Genes, T-Cell Receptor delta; Genes, T-Cell Receptor gamma; Humans; Imidazoles; Interferon-gamma; Lovastatin; Lung Neoplasms; Male; Membrane Glycoproteins; Neoplasms; Perforin; Pore Forming Cytotoxic Proteins; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Urinary Bladder Neoplasms; Vincristine; Zoledronic Acid | 2007 |
Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Diphosphonates; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Humans; Imidazoles; Lung Neoplasms; Zoledronic Acid | 2007 |
[Mediastinal lymph nodes during the course of a metastatic prostate cancer].
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyproterone; Diphosphonates; Estramustine; Fatal Outcome; Flutamide; Humans; Imidazoles; Ketoconazole; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Radionuclide Imaging; Skin Neoplasms; Triptorelin Pamoate; Zoledronic Acid | 2007 |
Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Disease Progression; Flow Cytometry; Imidazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Microscopy, Phase-Contrast; Neoplasms, Experimental; Survival Rate; Treatment Outcome; Zoledronic Acid | 2008 |
Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fibroblast Growth Factor 2; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2008 |
Zoledronic acid is effective against experimental malignant pleural effusion.
Topics: Animals; Apoptosis; Capillary Permeability; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Imidazoles; Leukocytes, Mononuclear; Lung Neoplasms; Macrophages; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neovascularization, Pathologic; Pleural Effusion, Malignant; Pleural Neoplasms; Zoledronic Acid | 2008 |
Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Pamidronate; Zoledronic Acid | 2008 |